| |
371 AP patients
|
|---|
| |
Total patients
|
Community acquired AP
|
Nosocomial AP
|
Community acquired Versus nosocomial AP
|
Urology
|
Infectious Diseases
|
Internal Medicine
|
Geriatrics
|
|---|
| |
n = 371
|
n = 293
|
n = 78
|
p value
|
n = 178
|
n = 115
|
n = 48
|
n = 30
|
|---|
|
Antibiotic treatment
| | | | | | | | |
|
Empirical choice
| | | | | | | | |
|
Bi-therapy
|
215 (58%)
|
172 (59%)
|
43 (55%)
|
0.7
|
123 (69%)
|
63 (55%)
|
20 (42%)
|
9 (30%)
|
|
Use of fluoroquinolone
|
234 (63%)
|
187 (64%)
|
47 (60%)
|
0.7
|
148 (83%)
|
47 (41%)
|
20 (42%)
|
19 (63%)
|
|
Use of 3rd generation cephalosporin
|
113 (30%)
|
85 (29%)
|
28 (36%)
|
0.3
|
25 (14%)
|
59 (51%)
|
22 (46%)
|
7 (23%)
|
|
Use of amino glycosides
|
195 (52%)
|
165 (56%)
|
30 (38%)
|
0.007
|
120 (67%)
|
60 (52%)
|
14 (29%)
|
1 (3%)
|
|
Use of other classes
|
44 (12%)
|
28 (10%)
|
16 (21%)
|
0.01
|
8 (4%)
|
12 (10%)
|
12 (25%)
|
12 (40%)
|
|
Inadequate*
|
42/269 (16%)
|
17/210 (8%)
|
25/59 (42%)
|
<0.001
|
27/137 (20%)
|
4/76 (5%)
|
6/31 (19%)
|
5/25 (25%)
|
|
Adapted choice
| | | | | | | | |
|
Bi-therapy
|
15 (4%)
|
13 (4%)
|
2(3%)
|
0.7
|
3 (2%)
|
11 (10%)
|
0 (0%)
|
1 (3%)
|
|
Use of fluoroquinolone
|
285 (77%)
|
242 (82%)
|
43 (55%)
|
<0.001
|
148 (83%)
|
85 (74%)
|
31 (65%)
|
21 (70%)
|
|
Use of 3rd generation cephalosporin
|
18 (5%)
|
11 (4%)
|
7 (9%)
|
0.1
|
9 (5%)
|
1 (1%)
|
5 (10%)
|
3 (10%)
|
|
Use of cotrimoxazole
|
52 (14%)
|
44 (15%)
|
8 (10%)
|
<0.001
|
13 (7%)
|
33 (29%)
|
5 (10%)
|
1 (3%)
|
|
Use of other classes
|
31 (8%)
|
9 (3%)
|
22 (28%)
|
<0.001
|
11 (6%)
|
7 (6%)
|
7 (15%)
|
6 (20%)
|
|
Inadequate*
|
18/269 (7%)
|
11/210 (5%)
|
7/59 (12%)
|
0.1
|
14/137 (10%)
|
1/76 (1%)
|
1/31 (3%)
|
2/25 (8%)
|
|
Total duration (days)
|
32
|
34
|
29
|
0.13
|
22
|
49
|
33
|
33
|
|
Bacterial failure at follow-up
|
37/153 (24%)
|
23/124 (19%)
|
14/29 (48%)
|
0.002
|
16/76 (21%)
|
2/32 (6%)
|
1/6 (16%)
|
4/9 (44%)
|
|
- same strain
|
7
|
3
|
4
| |
8
|
0
|
0
|
0
|
|
- other strain
|
30
|
20
|
10
| |
8
|
2
|
1
|
4
|
|
Clinical failure at follow-up
|
137/183 (75%)
|
98/135 (73%)
|
39/48 (83%)
|
0.3
|
88/123 (71%)
|
28/36 (78%)
|
8/10 (80%)
|
13/14 (92%)
|
- * The adequacy of the treatment was studied for the 169 patients with a positive urine culture and an antibiotic-resistance pattern of the pathogenic strain.
